Bifogade filer
PDF
Kurs & Likviditet
Kalender
| 2023-02-22 | Bokslutskommuniké 2022 |
| 2022-12-05 | Extra Bolagsstämma 2022 |
| 2022-07-21 | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | Årsstämma 2022 |
| 2022-05-06 | Ordinarie utdelning KARO 0.00 SEK |
| 2022-02-25 | Bokslutskommuniké 2021 |
| 2021-10-28 | Kvartalsrapport 2021-Q3 |
| 2021-07-22 | Kvartalsrapport 2021-Q2 |
| 2021-04-23 | Ordinarie utdelning KARO 0.00 SEK |
| 2021-04-21 | Årsstämma 2021 |
| 2021-04-21 | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | Bokslutskommuniké 2020 |
| 2020-10-30 | Kvartalsrapport 2020-Q3 |
| 2020-07-21 | Kvartalsrapport 2020-Q2 |
| 2020-05-25 | Årsstämma 2020 |
| 2020-04-30 | Ordinarie utdelning KARO 0.00 SEK |
| 2020-04-29 | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | Bokslutskommuniké 2019 |
| 2019-11-15 | Kvartalsrapport 2019-Q3 |
| 2019-09-20 | Extra Bolagsstämma 2019 |
| 2019-07-19 | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | Ordinarie utdelning KARO 0.00 SEK |
| 2019-05-16 | Årsstämma 2019 |
| 2019-04-26 | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | Bokslutskommuniké 2018 |
| 2018-11-01 | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | Ordinarie utdelning KARO 0.30 SEK |
| 2018-05-03 | Årsstämma 2018 |
| 2018-04-26 | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | Bokslutskommuniké 2017 |
| 2017-12-08 | Extra Bolagsstämma 2017 |
| 2017-11-02 | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | Bonusutdelning KARO 0.22 |
| 2017-05-12 | Ordinarie utdelning KARO 0.28 SEK |
| 2017-05-11 | Årsstämma 2017 |
| 2017-05-10 | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | Bokslutskommuniké 2016 |
| 2016-10-27 | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | Kvartalsrapport 2016-Q2 |
| 2016-05-13 | Ordinarie utdelning KARO 0.00 SEK |
| 2016-05-12 | Kvartalsrapport 2016-Q1 |
| 2016-05-12 | Årsstämma 2016 |
| 2016-03-16 | Extra Bolagsstämma 2016 |
| 2016-02-12 | Bokslutskommuniké 2015 |
| 2015-10-29 | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | Split KARO 20:1 |
| 2015-07-10 | Kvartalsrapport 2015-Q2 |
| 2015-04-30 | Ordinarie utdelning KARO 0.00 SEK |
| 2015-04-29 | Kvartalsrapport 2015-Q1 |
| 2015-04-29 | Årsstämma 2015 |
| 2015-02-13 | Bokslutskommuniké 2014 |
| 2014-10-29 | Kvartalsrapport 2014-Q3 |
| 2014-07-11 | Kvartalsrapport 2014-Q2 |
| 2014-05-09 | Ordinarie utdelning KARO 0.00 SEK |
| 2014-05-08 | Kvartalsrapport 2014-Q1 |
| 2014-05-08 | Årsstämma 2014 |
| 2014-03-17 | Extra Bolagsstämma 2014 |
| 2014-02-13 | Bokslutskommuniké 2013 |
| 2013-10-25 | Kvartalsrapport 2013-Q3 |
| 2013-07-12 | Kvartalsrapport 2013-Q2 |
| 2013-05-08 | Ordinarie utdelning KARO 0.00 SEK |
| 2013-05-07 | Årsstämma 2013 |
| 2013-05-07 | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | 15-7 2013 |
| 2013-02-12 | Analytiker möte 2013 |
| 2013-02-12 | Bokslutskommuniké 2012 |
| 2012-11-19 | Extra Bolagsstämma 2012 |
| 2012-10-24 | Kvartalsrapport 2012-Q3 |
| 2012-07-13 | Kvartalsrapport 2012-Q2 |
| 2012-06-12 | Årsstämma 2012 |
| 2012-04-30 | Ordinarie utdelning KARO 0.00 SEK |
| 2012-04-27 | Kvartalsrapport 2012-Q1 |
| 2012-02-08 | Bokslutskommuniké 2011 |
| 2011-11-29 | 15-7 2011 |
| 2011-10-25 | Kvartalsrapport 2011-Q3 |
| 2011-07-13 | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | Ordinarie utdelning KARO 0.00 SEK |
| 2011-04-27 | Kvartalsrapport 2011-Q1 |
| 2011-04-27 | Årsstämma 2011 |
| 2011-02-09 | Bokslutskommuniké 2010 |
| 2010-10-26 | Kvartalsrapport 2010-Q3 |
| 2010-07-13 | Kvartalsrapport 2010-Q2 |
| 2010-04-26 | Ordinarie utdelning KARO 0.00 SEK |
| 2010-04-23 | Årsstämma 2010 |
| 2010-04-22 | Kvartalsrapport 2010-Q1 |
| 2010-02-09 | Bokslutskommuniké 2009 |
| 2009-10-22 | Kvartalsrapport 2009-Q3 |
| 2009-07-14 | Kvartalsrapport 2009-Q2 |
| 2009-04-27 | Ordinarie utdelning KARO 0.00 SEK |
| 2009-04-24 | Årsstämma 1 |
| 2009-04-22 | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Karo Pharma Aktiebolag ("Karo Pharma") today announces that the acquisition of the intimate care and dermatology product portfolio from LEO Pharma for 90 MEUR, which was signed and announced by Karo Pharma on 23 December 2019 and approved by relevant competition authorities on 20 February 2020, has been completed.
The transaction is expected to contribute positively to Karo Pharma's market position within intimate care and dermatology and will support the ambitions to expand the European geographical footprint.
The acquired portfolio includes four anti-haemorrhoid products: Sheriproct®, Doloproct®, Neriproct® and Ultraproct® and six dermatology products that are mainly over-the-counter: Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®.
For further information, please contact:
Christoffer Lorenzen, CEO, +4673-501 76 20, christoffer.lorenzen@karopharma.com
Carl Lindgren, VP Business Development, +4676-002 60 22, carl.lindgren@karopharma.com
About Karo Pharma
Karo Pharma is a pharmaceutical company specialized in sales and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and retail. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.
This information is such information that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact persons set out above, at 12:00 CEST on 2 March 2020.